United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core. At about $23.5 billion in market value, it is one of the steadiest earners in biotech, and that is the whole point for index purposes. Most drug developers burn cash for years, but United Therapeutics books a positive profit under standard accounting rules almost every single quarter, the exact test that trips up its peers. The valuation reflects that reliability without stretching. The stock trades near 18 times trailing earnings and about 16 times next year’s expected profit, a modest multiple for a profitable, cash-generating healthcare company. UTHR is included in our coverage of 9 New Contenders for the S&P 500 Index.
DON’T MISS: 10 Best Growth Stocks to Buy Now According to Billionaires
Bull Case
The bull case is consistency plus fresh catalysts. United Therapeutics earns a positive GAAP profit essentially every quarter, the exact hurdle most biotechs fail, so it clears the profitability screen with room to spare. Lately, the news has broken in its favor. Its pulmonary-hypertension franchise just won key patent protection for Tyvaso, and a $380.7 million settlement with rival Liquidia cleared a legal overhang that had weighed on the stock. The pipeline is deepening too, with the FDA accepting filings for a nebulized version of Tyvaso and for ralinepag, a potential next-generation treatment. Each of these extends the runway on a franchise that already throws off steady cash, which is why a company this profitable can keep funding research without leaning on outside money.
Looking for affordable stocks to buy? Check out our 10 best affordable stocks to buy.
Bear Case
The bear case is size, competition, and concentration. United Therapeutics sits slightly above the index size minimum, near $23 billion, so a weak stretch could nudge it back below the line. Competition is heating up in pulmonary hypertension, and Goldman Sachs just started coverage with a Sell rating, pointing to that rivalry and to regulatory risk around the pipeline. The deeper worry is concentration. So much of the profit rests on the Tyvaso family that any setback there – a new competing therapy, a pricing change, or a trial disappointment – would hit the whole company at once. A business this dependent on one drug franchise carries more single-point risk than its steady earnings record might suggest at first glance.
The stock declined by 4.29% across the trailing six months. By comparison, the Insider Monkey Billionaire Index gained 11.6%.
Bottom Line
The bottom line is that United Therapeutics has one of the cleanest eligibility profiles on this list. It is a US company, it is large enough, its shares trade heavily, and above all it delivers the consistent GAAP profits that the screen demands and that so many biotechs cannot. It would also add healthcare balance to a contender pool heavy on technology and finance. What keeps it a debate rather than a lock is the competitive and concentration risk Goldman flagged, which could pressure the very earnings that make it eligible. Whether a steady, single-franchise biotech at a reasonable multiple suits you is your call.
Market Sentiment
On positioning, Insider Monkey’s database shows interest edged higher, with 68 hedge funds holding United Therapeutics Corporation at the end of the second quarter of 2026, up from 64 the quarter before.
To check out the rest of the contending companies in 9 New Contenders for the S&P 500 Index, click HERE.
READ NEXT: Waste Management (WM) vs. Republic Services (RSG): Which Trash Giant Is the Better Buy? and Sherwin-Williams (SHW) vs. PPG Industries (PPG): Which Paint Giant Is the Better Buy?
This article is originally published at Insider Monkey.
